BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Levin JM, Dabirshahsahebi S, Bauer M, Huckins E. Retrospective analysis of hepatitis C infected patients treated through an integrated care model. World J Gastroenterol 2016; 22(38): 8558-8567 [PMID: 27784968 DOI: 10.3748/wjg.v22.i38.8558]
URL: https://www.wjgnet.com/1007-9327/full/v22/i38/8558.htm
Number Citing Articles
1
Mi Seon Park, Young-Mo Yang, Ki Hyun Park, Hyonok Yoon, Ju Sin Kim, Eun Joo Choi. Assessing the Effectiveness and Safety of Direct-acting Antiviral Treatment in Korean Patients with Hepatitis C Virus Genotype 1b or 2 at a Tertiary Care HospitalKorean Journal of Clinical Pharmacy 2022; 32(3): 191 doi: 10.24304/kjcp.2022.32.3.191
2
Fabian Chiong, Jeffrey Post. Opportunistic assessment and treatment of people with hepatitis C virus infection admitted to hospital for other reasons: A prospective cohort studyInternational Journal of Drug Policy 2019; 65: 50 doi: 10.1016/j.drugpo.2018.11.003
3
Autumn Zuckerman, Alicia Carver, Cody A. Chastain. Building a Hepatitis C Clinical Program: Strategies to Optimize OutcomesCurrent Treatment Options in Infectious Diseases 2018; 10(4): 431 doi: 10.1007/s40506-018-0177-5
4
Haruna Yamamoto, Hiroaki Ikesue, Mai Ikemura, Rieko Miura, Kazumi Fujita, Hobyung Chung, Yoshiki Suginoshita, Tetsuro Inokuma, Tohru Hashida. Evaluation of pharmaceutical intervention in direct-acting antiviral agents for hepatitis C virus infected patients in an ambulatory setting: a retrospective analysisJournal of Pharmaceutical Health Care and Sciences 2018; 4(1) doi: 10.1186/s40780-018-0113-3
5
Erik J. Groessl, Lin Liu, Marisa Sklar, Samuel B. Ho. HCV Integrated Care: A Randomized Trial to Increase Treatment Initiation and SVR with Direct Acting AntiviralsInternational Journal of Hepatology 2017; 2017: 1 doi: 10.1155/2017/5834182